ArticleBMC cardiovascular disorders2025
Effect of serum ferritin on the prognosis of patients with coronary heart disease combined with heart failure.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the effect of serum ferritin (SF) on the prognosis of patients with coronary artery disease combined with heart failure.
methodsWe retrospectively included 3,424 adult patients with combined coronary artery disease (CAD) and chronic heart failure (CHF) from an initial screening of 4,442 patients. Inclusion criteria were age ≥ 18 years, presence of CAD (≥ 50% stenosis of major vessels) confirmed by angiography, and fulfillment of the European Society of Cardiology (ESC) guidelines for the diagnosis of CHF. One thousand one hundred and eight patients who might interfere with the primary outcome were excluded, including those with comorbid advanced cancer, severe organ dysfunction, immune or psychiatric disorders, and those with recent major trauma/surgery. Patients were categorized into a high SF group (≥ 230.465 ng/ml) versus a low SF group (< 230.465 ng/ml) based on the optimal threshold value of serum ferritin (SF). Clinical data were collected for between-group comparison and all-cause mortality assessment. Kaplan-Meier curves were used for survival analysis and differences between groups were compared by log-rank test; multivariate Cox regression analysis was also applied to screen independent risk factors affecting patients' prognosis.
resultCompared with the group with low SF values, the percentage of men, all-cause mortality, and B-type Natriuretic Peptide (BNP) were higher in the group with high SF values than in the group with low SF values (P < 0.05); After adjusting for potential confounders, the multivariable Cox regression analysis identified that age, albumin, and high-density lipoprotein were independent factors affecting survival risk, and the high SF group had a 47% higher risk of events compared to the low SF group. (HR:1.472, 95%CI: 1.174-1.846 P = 0.001).
conclusionSF is an important prognostic biomarker in patients with coronary artery disease combined with heart failure, independent of traditional risk factors, and elevated SF levels are associated with poor prognosis in patients with coronary artery disease combined with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.